{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:35:40Z","timestamp":1792488940099,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.drudis.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:52:56Z","timestamp":1649771576000},"page":"1874-1894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Repurposing drugs targeting epidemic viruses"],"prefix":"10.1016","volume":"27","author":[{"given":"Vigneshwaran","family":"Namasivayam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthikumar","family":"Palaniappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesan","family":"Vanangamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.04.008_b0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2022.04.008_b0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2019.00549","article-title":"Infectious disease threats in the twenty-first century: strengthening the global response","volume":"10","author":"Bloom","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.drudis.2022.04.008_b0020","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.04.008_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens","volume":"54","author":"Vanangamudi","year":"2020","journal-title":"Curr Opin Pharmacol"},{"issue":"16","key":"10.1016\/j.drudis.2022.04.008_b0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/CM9.0000000000000376","article-title":"First outbreak of human infection with avian influenza A(H7N9) virus in Guangxi, China, 2016 to 2017","volume":"132","author":"Wang","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.drudis.2022.04.008_b0035","doi-asserted-by":"crossref","first-page":"674277","DOI":"10.3389\/fcimb.2021.674277","article-title":"Clinical predictors of COVID-19 severity and mortality: a perspective","volume":"11","author":"Sharma","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.drudis.2022.04.008_b0040","doi-asserted-by":"crossref","first-page":"637550","DOI":"10.3389\/fmolb.2021.637550","article-title":"An overview of spike surface glycoprotein in severe acute respiratory syndrome-coronavirus","volume":"8","author":"Kathiravan","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.drudis.2022.04.008_b0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fviro.2021.666548","article-title":"Vaccines and antivirals: grand challenges and great opportunities","volume":"1","author":"Andrei","year":"2021","journal-title":"Front Virol"},{"key":"10.1016\/j.drudis.2022.04.008_b0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","article-title":"Comparison of antiviral resistance across acute and chronic viral infections","volume":"158","author":"Mason","year":"2018","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0055","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem Soc Rev"},{"issue":"4","key":"10.1016\/j.drudis.2022.04.008_b0060","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2014.12.054","article-title":"Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein","volume":"10","author":"Strating","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2022.04.008_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2021.666548","article-title":"Vaccines and antivirals: grand challenges and great opportunities","author":"Andrei","year":"2021","journal-title":"Front Virol"},{"key":"10.1016\/j.drudis.2022.04.008_b0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-16-0267-2_3","article-title":"Structural insights to human immunodeficiency virus (HIV-1) targets and their inhibition","volume":"1322","author":"Vanangamudi","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"7154","key":"10.1016\/j.drudis.2022.04.008_b0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.drudis.2022.04.008_b0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2022.04.008_b0090","unstructured":"Global drug repurposing market report, history and forecast 2016\u20132027, breakdown data by companies, key regions, types and application. Market Reports World. www.marketreportsworld.com\/global-drug-repurposing-market-18342783 [Accessed April 5, 2022]."},{"issue":"8","key":"10.1016\/j.drudis.2022.04.008_b0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17460441.2021.1912733","article-title":"Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?","volume":"16","author":"Gil","year":"2021","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"10.1016\/j.drudis.2022.04.008_b0100","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3201\/eid2207.151990","article-title":"A literature review of Zika virus","volume":"22","author":"Plourde","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.drudis.2022.04.008_b0105","unstructured":"Zika virus. WHO. www.who.int\/news-room\/fact-sheets\/detail\/zika-virus [Accessed April 5, 2022]."},{"key":"10.1016\/j.drudis.2022.04.008_b0110","unstructured":"Data and Statistics on Zika and Pregnancy. CDC. www.cdc.gov\/pregnancy\/zika\/data\/index.html [Accessed April 5, 2022]."},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika Virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.04.008_b0120","doi-asserted-by":"crossref","first-page":"40920","DOI":"10.1038\/srep40920","article-title":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0125","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.04.008_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov"},{"issue":"5","key":"10.1016\/j.drudis.2022.04.008_b0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"8","key":"10.1016\/j.drudis.2022.04.008_b0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/cr.2017.88","article-title":"Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction","volume":"27","author":"Li","year":"2017","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bjid.2020.09.001","article-title":"Inhibition of Brazilian ZIKV strain replication in primary human placental chorionic cells and cervical cells treated with nitazoxanide","volume":"24","author":"de Souza","year":"2020","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.drudis.2022.04.008_b0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2017.07.007","article-title":"Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo","volume":"145","author":"Yuan","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.antiviral.2017.02.002","article-title":"Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor","volume":"141","author":"Chan","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","article-title":"Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice","volume":"24","author":"Li","year":"2017","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.drudis.2022.04.008_b0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A Screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2022.04.008_b0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0175","first-page":"57","article-title":"General introduction into the Ebola virus biology and disease","volume":"54","author":"Zawili\u0144ska","year":"2014","journal-title":"Folia Med Cracov"},{"issue":"7624","key":"10.1016\/j.drudis.2022.04.008_b0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nature19790","article-title":"The evolution of Ebola virus: insights from the 2013\u20132016 epidemic","volume":"538","author":"Holmes","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1871526515666150320162259","article-title":"Ebola virus: current and future perspectives","volume":"15","author":"Jadav","year":"2015","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.drudis.2022.04.008_b0190","unstructured":"Ebola (Ebola Virus Disease). CDC. www.cdc.gov\/vhf\/ebola\/index.html [Accessed April 5, 2022]."},{"key":"10.1016\/j.drudis.2022.04.008_b0195","unstructured":"Ebola virus disease. WHO. www.who.int\/news-room\/fact-sheets\/detail\/ebola-virus-disease [Accessed April 5, 2022]."},{"key":"10.1016\/j.drudis.2022.04.008_b0200","doi-asserted-by":"crossref","first-page":"104908","DOI":"10.1016\/j.antiviral.2020.104908","article-title":"Repurposing Pyramax\u00ae, quinacrine and tilorone as treatments for Ebola virus disease","volume":"182","author":"Lane","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","article-title":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture","volume":"125","author":"Wang","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0210","doi-asserted-by":"crossref","first-page":"173553","DOI":"10.1016\/j.ejphar.2020.173553","article-title":"Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review","volume":"887","author":"Otr\u0119ba","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2022.04.008_b0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.curtheres.2017.01.007","article-title":"Repurposed therapeutic agents targeting the Ebola virus: a systematic review","volume":"84","author":"Sweiti","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"issue":"290","key":"10.1016\/j.drudis.2022.04.008_b0220","doi-asserted-by":"crossref","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.04.008_b0225","doi-asserted-by":"crossref","first-page":"e01412","DOI":"10.1016\/j.idcr.2022.e01412","article-title":"High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea","volume":"27","author":"Eloy","year":"2022","journal-title":"IDCases"},{"issue":"9","key":"10.1016\/j.drudis.2022.04.008_b0230","doi-asserted-by":"crossref","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental treatment of Ebola virus disease with brincidofovir","volume":"11","author":"Dunning","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0235","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1038\/s41467-019-13562-y","article-title":"Epidemic dynamics of respiratory syncytial virus in current and future climates","volume":"10","author":"Baker","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0240","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","article-title":"Respiratory syncytial virus\u2013a comprehensive review","volume":"45","author":"Borchers","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.drudis.2022.04.008_b0245","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1542\/pir.35.12.519","article-title":"Respiratory syncytial virus infection and bronchiolitis","volume":"35","author":"Piedimonte","year":"2014","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.drudis.2022.04.008_b0250","doi-asserted-by":"crossref","first-page":"198277","DOI":"10.1016\/j.virusres.2020.198277","article-title":"Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication","volume":"295","author":"Niyomdecha","year":"2021","journal-title":"Virus Res"},{"issue":"4","key":"10.1016\/j.drudis.2022.04.008_b0255","doi-asserted-by":"crossref","first-page":"e203482","DOI":"10.1001\/jamanetworkopen.2020.3482","article-title":"Azithromycin treatment vs placebo in children with respiratory syncytial virus-induced respiratory failure: a phase 2 randomized clinical trial","volume":"3","author":"Kong","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.04.008_b0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2018.01.012","article-title":"Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation","volume":"151","author":"Kim","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0270","doi-asserted-by":"crossref","first-page":"23110","DOI":"10.1038\/srep23110","article-title":"Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model","volume":"6","author":"Shim","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.drudis.2022.04.008_b0275","doi-asserted-by":"crossref","first-page":"e1002976","DOI":"10.1371\/journal.ppat.1002976","article-title":"Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects","volume":"8","author":"Jurgeit","year":"2012","journal-title":"PLoS Pathogens"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0280","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.antiviral.2012.03.005","article-title":"Quercetin inhibits rhinovirus replication in vitro and in vivo","volume":"94","author":"Ganesan","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0285","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2017.07.003","article-title":"Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo","volume":"145","author":"Song","year":"2017","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0290","first-page":"211","article-title":"Chikungunya virus infection: an overview","volume":"36","author":"Caglioti","year":"2013","journal-title":"New Microbiol"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0295","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.drudis.2022.04.008_b0300","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.drudis.2022.04.008_b0305","unstructured":"Chikungunya. WHO. www.who.int\/news-room\/fact-sheets\/detail\/chikungunya. [Accessed April 5, 2022]."},{"issue":"5","key":"10.1016\/j.drudis.2022.04.008_b0310","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jmv.21663","article-title":"Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells","volume":"82","author":"Khan","year":"2010","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.drudis.2022.04.008_b0315","doi-asserted-by":"crossref","first-page":"e11479","DOI":"10.1371\/journal.pone.0011479","article-title":"Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments","volume":"5","author":"Bernard","year":"2010","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0320","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/v12030314","article-title":"Suramin inhibits Chikungunya virus replication by interacting with virions and blocking the early steps of infection","volume":"12","author":"Albulescu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2022.04.008_b0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2016.07.025","article-title":"Suramin treatment reduces chikungunya pathogenesis in mice","volume":"134","author":"Kuo","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2018.10.005","article-title":"Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms","volume":"159","author":"Ho","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0335","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.virol.2020.05.010","article-title":"Evaluation of novobiocin and telmisartan for anti-CHIKV activity","volume":"548","author":"Tripathi","year":"2020","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.drudis.2022.04.008_b0340","doi-asserted-by":"crossref","first-page":"e00487","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.drudis.2022.04.008_b0345","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2022.04.008_b0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.antiviral.2017.09.016","article-title":"Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection","volume":"149","author":"Abdelnabi","year":"2018","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.drudis.2022.04.008_b0355","doi-asserted-by":"crossref","first-page":"e01389","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits Chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0360","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s43440-021-00216-4","article-title":"Memantine hydrochloride: a drug to be repurposed against Chikungunya virus?","volume":"73","author":"Pereira","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"8","key":"10.1016\/j.drudis.2022.04.008_b0365","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.medmal.2019.09.005","article-title":"Crimean-Congo hemorrhagic fever: an update","volume":"49","author":"Fill\u00e2tre","year":"2019","journal-title":"Med Mal Infect"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0370","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1309\/LMN1P2FRZ7BKZSCO","article-title":"Crimean-Congo hemorrhagic fever","volume":"46","author":"Shayan","year":"2015","journal-title":"Lab Med"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0375","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/JVI.01859-09","article-title":"Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function","volume":"84","author":"Bergeron","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.04.008_b0380","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.12688\/f1000research.16189.1","article-title":"Recent advances in understanding Crimean-Congo hemorrhagic fever virus","volume":"7","author":"Hawman","year":"2018","journal-title":"F1000Res"},{"issue":"12","key":"10.1016\/j.drudis.2022.04.008_b0385","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/infdis\/jiy163","article-title":"Ribavirin had demonstrable effects on the Crimean-Congo hemorrhagic fever virus (CCHFV) population and load in a patient with CCHF infection","volume":"217","author":"Espy","year":"2018","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.drudis.2022.04.008_b0390","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.drudis.2022.04.008_b0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2015.03.005","article-title":"Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules","volume":"118","author":"Ferraris","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0400","unstructured":"Cytomegalovirus (CMV) and Congenital CMV Infection. CDC, www.cdc.gov\/cmv\/overview.html [Accessed April 5, 2022]."},{"key":"10.1016\/j.drudis.2022.04.008_b0405","doi-asserted-by":"crossref","first-page":"104119","DOI":"10.1016\/j.meegid.2019.104119","article-title":"Human cytomegalovirus-encoded MicroRNAs: a master regulator of latent infection","volume":"78","author":"Abdalla","year":"2020","journal-title":"Infect Genet Evol"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-783X-18-3","article-title":"Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus","volume":"18","author":"Qi","year":"2013","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0415","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0420","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0425","doi-asserted-by":"crossref","first-page":"e01861","DOI":"10.1128\/JVI.01861-17","article-title":"Digitoxin suppresses human cytomegalovirus replication via Na(+), K(+)\/ATPase \u03b11 subunit-dependent AMP-activated protein kinase and autophagy activation","volume":"92","author":"Mukhopadhyay","year":"2018","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0430","doi-asserted-by":"crossref","first-page":"e1005717","DOI":"10.1371\/journal.ppat.1005717","article-title":"Efficacy and mechanism of action of low dose emetine against human cytomegalovirus","volume":"12","author":"Mukhopadhyay","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.04.008_b0435","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2017.12.014","article-title":"Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein","volume":"150","author":"Mercorelli","year":"2018","journal-title":"Antiviral Res"},{"issue":"10","key":"10.1016\/j.drudis.2022.04.008_b0440","doi-asserted-by":"crossref","first-page":"e00056","DOI":"10.1128\/AAC.00056-20","article-title":"The clinically approved antifungal drug posaconazole inhibits human cytomegalovirus replication","volume":"64","author":"Mercorelli","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.04.008_b0445","doi-asserted-by":"crossref","first-page":"105062","DOI":"10.1016\/j.antiviral.2021.105062","article-title":"The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs","volume":"189","author":"Mercorelli","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0450","unstructured":"Dengue and severe dengue. WHO. www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue [Accessed April 5, 2022]."},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41426-018-0168-0","article-title":"Dengue virus and the host innate immune response","volume":"7","author":"Uno","year":"2018","journal-title":"Emerg Microbes Infect"},{"issue":"suppl_2","key":"10.1016\/j.drudis.2022.04.008_b0460","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/infdis\/jiw649","article-title":"Clinical and laboratory diagnosis of dengue virus Infection","volume":"215","author":"Muller","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.drudis.2022.04.008_b0465","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CMR.00035-09","article-title":"Dengue virus pathogenesis: an integrated view","volume":"22","author":"Martina","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.04.008_b0470","doi-asserted-by":"crossref","first-page":"282734","DOI":"10.1155\/2013\/282734","article-title":"Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6\/36 cells","volume":"2013","author":"Farias","year":"2013","journal-title":"ScientificWorldJournal"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0475","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/vim.2014.0090","article-title":"Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys","volume":"28","author":"Farias","year":"2015","journal-title":"Viral Immunol"},{"key":"10.1016\/j.drudis.2022.04.008_b0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2016.06.002","article-title":"Towards antiviral therapies for treating dengue virus infections","volume":"30","author":"Kaptein","year":"2016","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.drudis.2022.04.008_b0485","doi-asserted-by":"crossref","first-page":"e87412","DOI":"10.1371\/journal.pone.0087412","article-title":"Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2","volume":"9","author":"Martinez-Gutierrez","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.04.008_b0490","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2741\/4630","article-title":"Drug repurposing approaches to fight Dengue virus infection and related diseases","volume":"23","author":"Botta","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.drudis.2022.04.008_b0495","unstructured":"Pharmacokinetics and pharmacodynamics of ivermectin in pediatric dengue patients (PKIDEN). US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03432442 [Accessed April 5, 2022]."},{"issue":"18","key":"10.1016\/j.drudis.2022.04.008_b0500","doi-asserted-by":"crossref","first-page":"e00617","DOI":"10.1128\/JVI.00617-17","article-title":"Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a dengue disease model","volume":"91","author":"Morrison","year":"2017","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.drudis.2022.04.008_b0505","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiu377","article-title":"Repurposing of prochlorperazine for use against dengue virus infection","volume":"211","author":"Simanjuntak","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0510","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbrc.2016.07.029","article-title":"Drug repurposing of minocycline against dengue virus infection","volume":"478","author":"Leela","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.04.008_b0515","doi-asserted-by":"crossref","first-page":"606743","DOI":"10.3389\/fcimb.2020.606743","article-title":"Repurposing the antiemetic metoclopramide as an antiviral against dengue virus infection in neuronal cells","volume":"10","author":"Shen","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.drudis.2022.04.008_b0520","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.antiviral.2019.03.011","article-title":"Drug repurposing of N-acetyl cysteine as antiviral against dengue virus infection","volume":"166","author":"Sreekanth","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.04.008_b0525","unstructured":"Yellow Fever. WHO. www.who.int\/news-room\/fact-sheets\/detail\/yellow-fever [Accessed April 5, 2022]."},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0530","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","article-title":"Yellow fever: an update","volume":"1","author":"Monath","year":"2001","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.drudis.2022.04.008_b0535","doi-asserted-by":"crossref","first-page":"e01623","DOI":"10.1128\/JVI.01623-19","article-title":"Yellow fever virus reemergence and spread in southeast Brazil, 2016\u20132019","volume":"94","author":"Giovanetti","year":"2019","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.drudis.2022.04.008_b0540","doi-asserted-by":"crossref","first-page":"e00827","DOI":"10.1128\/JCM.00827-18","article-title":"Yellow fever virus: diagnostics for a persistent arboviral threat","volume":"56","author":"Waggoner","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.drudis.2022.04.008_b0545","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.aohep.2019.09.001","article-title":"Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure","volume":"18","author":"Mendes","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.drudis.2022.04.008_b0550","first-page":"225656","article-title":"Drug repurposing for yellow fever using high content screening","author":"Pilger","year":"2017","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2022.04.008_b0555","unstructured":"Lassa fever. WHO. www.who.int\/news-room\/fact-sheets\/detail\/lassa-fever [Accessed April 5, 2022]."},{"key":"10.1016\/j.drudis.2022.04.008_b0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.16989.1","article-title":"Lassa virus diversity and feasibility for universal prophylactic vaccine","volume":"8","author":"Lukashevich","year":"2019","journal-title":"F1000Res"},{"issue":"16","key":"10.1016\/j.drudis.2022.04.008_b0565","doi-asserted-by":"crossref","first-page":"e00954","DOI":"10.1128\/JVI.00954-18","article-title":"Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library","volume":"92","author":"Wang","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.04.008_b0570","doi-asserted-by":"crossref","first-page":"104701","DOI":"10.1016\/j.antiviral.2019.104701","article-title":"The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein","volume":"174","author":"Zhang","year":"2020","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.drudis.2022.04.008_b0575","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: the virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.drudis.2022.04.008_b0580","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrneurol.2018.30","article-title":"Japanese encephalitis - the prospects for new treatments","volume":"14","author":"Turtle","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.drudis.2022.04.008_b0585","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/molecules23123346","article-title":"Drug repurposing for Japanese encephalitis virus infection by systems biology methods","volume":"23","author":"Lv","year":"2018","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.drudis.2022.04.008_b0590","doi-asserted-by":"crossref","first-page":"e01055","DOI":"10.1128\/JVI.01055-17","article-title":"Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.04.008_b0595","article-title":"Open science discovery of oral non-covalent SARS-CoV-2 main protease inhibitor therapeutics","author":"The","year":"2022","journal-title":"bioRxiv"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:58:09Z","timestamp":1761224289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":119,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1359644622001556"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.008","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing drugs targeting epidemic viruses","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}